1. Pink Sheet
  3. >>North America

USCMA Revision Worsens Innovator Woes In Canada

News Comes As Consultation On New Pricing Guidelines Is Extended

 
• By Francesca Bruce

Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.

USMCA_Flags
Revised USMCA Could Make Things Tougher For Innovators In Canada • Source: Shutterstock

The removal of provisions that would have toughened biologic exclusivity from the NAFTA replacement deal between the US, Canada and Mexico will hurt investment in Canadian R&D and make the country less competitive, the research-based pharmaceutical industry there has warned. Attracting new investment in Canada is already more difficult because of changes to pricing regulations aimed at cutting drug prices, Innovative Medicines Canada claims.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Canada

More from North America

US FDA Commissioner’s Office Plans Involvement In Many Approvals In Potential Major Change

 
• By Sarah Karlin-Smith

FDA Commissioner Martin Makary's remarks that his special assistant Tracy Beth Høeg will "be involved in other approval procedures" besides Novavax's COVID-19 vaccine application could be a dramatic change in operations, potentially making the approval system unpredictable.

Another Regeneron CRL Prompts Regulatory Operations Questions

 
• By Alaric DeArment

CEO Len Schleifer said during the company’s first quarter earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.